ABEO - Abeona Therapeutics Company Long-Term Liabilities

Graphic logo of abeonatherapeutics.com (ABEO)

Abeona Therapeutics (ABEO) maintains a high reputation in the field of gene therapy for orphan diseases, developing cutting-edge tools for tissue regeneration. The business's success relies on FDA certification and a flawless technical process, while long-term debt stands at 0.01. This price chart clearly illustrates the issuer's market dynamics. The company is currently scaling its distribution network and optimizing supply chains for its flagship product.

Company Long-Term Debts: Abeona Therapeutics, Inc. (ABEO) for 07/04/2022 - 10/31/2026

Abeona Therapeutics Inc. (ABEO) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price Abeona Therapeutics, Inc.|ABEO - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Abeona Therapeutics|ABEO - Enterprise Value
- shareholders' equity book value data:
Net Assets per Share Abeona Therapeutics|ABEO - Book Capitalization|Market Capitalization to Book Value Ratio abeonatherapeutics.com|ABEO - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Abeona Therapeutics|ABEO - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Abeona Therapeutics, Inc.|ABEO - Company Total Debt|Debts to Book Capitalization Ratio Abeona Therapeutics|ABEO - Company Long-Term Debts|Short-Term Debt Abeona Therapeutics|Immediate Liquidity Ratio abeonatherapeutics.com
- company profitability and valuation multiples indicators:
ABEO - Net Income
Fundamental company valuation:Abeona Therapeutics, ABEO
Manufactured products of Abeona Therapeutics

For gene therapy leader Abeona Therapeutics (ABEO), the current level of long-term debt reflects the financing strategy for the development of the EB-101 drug. This indicator aggregates obligations with maturities exceeding one year, capturing the pace of deleveraging during the company's recovery period. The metric measures the debt load, allowing for an assessment of the capital structure's stability in the absence of steady revenue. It is critical for investors to weigh debt reduction against liquidity risks and the availability of resources for vector production.

Who Abeona Therapeutics competes with

vrtx.com (VRTX) - Long-Term Debt|Alnylam - Company Long-Term Debts|Insmed Inc. (INSM) - Company Long-Term Liabilities|UTHR: Company Long-Term Debts|BMRN - Long-Term Debt Volume|BBIO (BridgeBio Pharma, Inc.) - Company Long-Term Debts|Company Long-Term Debts BGM Group Corp|Company Long-Term Debt Cogent Biosciences, Inc. (COGT)|Company Long-Term Debt XERS (Xeris Biopharma Holdings, Inc.)|Company Long-Term Debts KROS (Keros Pharma)|Long-Term Debt Volume Arcturus Corp (ARCT)|ETON: Company Long-Term Liabilities|Long-Term Liabilities KMDA|FULC: Company Long-Term Debts|Long-Term Debt Mereo BioPharma Group plc (MREO)|PLX (Protalix) - Company Long-Term Debts|Company Long-Term Indebtedness PLRX (Pliant Rx)|Company Long-Term Liabilities APLT (Applied Therapeutics, Inc.)|RNTX (aileronrx.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Gelteq GELS|AYTU (Aytu BioPharma Inc) - Long-Term Liabilities|Chemomab - Company Long-Term Debts|Company Long-Term Loans and Borrowings SRXH (SRx Health Solutions Inc.)|PLRZ: Company Long-Term Debts|Aeterna Zentaris Inc. (AEZS) - Company Long-Term Debts|Company Long-Term Debt Cyclo Therapeutics, Inc.|INZY: Company Long-Term Loans and Borrowings|Company Long-Term Debt Reneo Pharma (RPHM)|Company Long-Term Liabilities COSCIENS Bio CSCI